a Background: HAART has been associated with metabolic abnormalities (hyperlipidemia, insulin resistance, alterations in cortisol metabolism) and fat redistribution.
Introduction
Highly active antiretroviral therapy (HAART) has led to signi®cant improvements in mortality and morbidity resulting from HIV-1 infection among patients with access to these drugs [1, 2] . However, an unusual complex of side effects has been associated with its use. Many investigators have described a syndrome consisting of metabolic abnormalities (hyperlipidemia, peripheral insulin resistance, alterations in cortisol metabolism) and abnormalities in body fat distribution (accumulation of visceral abdominal fat, development of dorsocervical fat pads and loss of facial and extremity fat) [3±8] . Attempts to de®ne this syndrome have been dif®cult and it is not yet clear whether it constitutes a single entity or a family of syndromes [9, 10] . The changes in body habitus can be particularly troubling to the patient. Moreover, it is yet to be determined whether hyperlipidemia and insulin resistance are associated with an increased risk of cardiovascular disease in HIV-positive patients [11, 12] , as they are in the HIVnegative population [13, 14] .
Many theories have been proposed to explain the mechanisms underlying these metabolic and fat distribution abnormalities [15±20] . Initially, the symptoms were attributed speci®cally to the use of protease inhibitors (PI) [4±7] . However, more recent studies have reported similar ®ndings in PI-naive patients taking nucleoside reverse transcriptase inhibitors (NRTI) [21] . Some researchers have proposed that these changes may be a direct result of chronic HIV infection itself rather than a side effect of antiretroviral therapy, although it has been dif®cult to separate the effects of HIV infection from those of antiretroviral exposure [22] . This has been examined in a group of patients interrupting HAART to see whether these abnormalities improved with a temporary interruption of therapy.
Methods

Study protocol and patients
The study was part of a prospective evaluation of the immunologic and virologic consequences of interrupting HAART [23] conducted at the National Institute of Allergy and Infectious Diseases (NIAID)/ Critical Care Medicine Department HIV Research Clinic at the National Institutes of Health.
Criteria for study participation have been described in detail elsewhere [23] and included con®rmed HIV infection, age > 18 years, continuous HAART (de®ned as a regimen consisting of at least one PI and two NRTI) for > 12 months, HIV-1 viral load , 500 copies/ml for > 12 months, HIV-1 viral load , 50 copies/ml on two determinations within 30 days prior to enrollment in the study and total CD4 cell count > 350 3 10 6 cells/l on three determinations within 30 days prior to enrollment. None of the patients were studied during the period of acute retroviral seroconversion.
Criteria for restarting HAART were prospectively de®ned as a decline in total CD4 cell count by > 25% from baseline, a viral load > 5000 copies/ml, or at patient request.
All patients provided written informed consent as approved by the NIAID Institutional Review Board.
Viral and immunologic measurements
Duration of known HIV infection, highest recorded viral load, and lowest recorded CD4 cell count were obtained from patient records. Viral burden and CD4 cell counts were measured prior to the cessation of HAART and weekly during the period of drug interruption. HIV-1 viral loads were measured with the Quantiplex HIV-1 RNA (bDNA) Assay version 3.0, with a lower limit of detection of 50 copies/ml (Bayer Diagnostics, Norwood, Massachusetts, USA). CD4 cell counts were measured by¯ow cytometry.
Metabolic studies
Metabolic measurements were made for each patient at two timepoints: before HAART interruption (baseline) and prior to its reinstitution (end-of-study).
Fasting serum total cholesterol, high density lipoprotein (HDL) cholesterol, and triglycerides were measured by standard clinical laboratory methods, as previously described [7] . Low density lipoprotein (LDL) cholesterol levels were calculated from total cholesterol and HDL cholesterol levels. Hyperlipidemia was de®ned as total cholesterol . 200 mg/dl, LDL cholesterol . 130 mg/dl, HDL cholesterol , 35 mg/dl and/or triglycerides . 160 mg/dl.
Patients also underwent an oral glucose tolerance test (OGTT). After a 12-h overnight fast, patients ingested 75 g dextrose. Blood samples were collected at 0, 60, 90, and 120 min thereafter for determination of glucose and insulin levels. Glucose and insulin levels were measured as previously described [7] . The area under the curve (AUC) for glucose and insulin was determined by combining values from the four OGTT timepoints. Insulin resistance was estimated by the homeostasis model assessment for insulin resistance (HOMA-IR) using the equation [24] HOMA-IR [fasting insulin (mIU/l) 3 fasting glucose (mmol/l)]/ 22.5. An abnormal fasting HOMA-IR at time 0 was de®ned as . 2.56 [25] .
Cortisol metabolism was examined by measuring 24-h excretion of urinary free cortisol and 17-hydroxycorticosteroids (17-OHCS), as previously described [26] .
Fat redistribution and anthropometric measurements During the initial screening visit, patients were asked whether they had experienced any changes in body habitus. In the ®rst 17 patients, visceral abdominal fat was measured by abdominal computed tomography (CT) at baseline, as previously described [5] . Visceral adipose tissue (VAT) and total adipose tissue (TAT) were measured at the umbilicus (L4 vertebral level) and a VAT:TAT ratio was calculated. An abnormal VAT:-TAT ratio was de®ned as . 0.4 [27, 28] .
The following anthropometric measurements were made at baseline and at end-of-study in all patients using standardized methods [29] : weight, height, waist (abdominal) circumference, hip circumference, midarm circumference, mid-forearm circumference, midthigh circumference, and mid-calf circumference. Abdominal, medial calf, triceps, biceps, subscapular and suprailiac skinfolds were also measured. Body weight was measured to the nearest 0.1 kg using a platform digital scale and stadiometer height was measured to the nearest 0.1 cm. All circumferences were measured to the nearest 0.1 cm with a non-stretch tape measure. Waist (abdominal) circumference was measured at the level of the iliac crests. Skinfolds were measured to the nearest 0.5 mm on the right side using Lange skinfold calipers (Cambridge Scienti®c Industries, Inc., Cambridge, Massachusetts, USA). All measurements were made in triplicate; a mean of the three values was used in the analysis.
Body mass index and waist to hip ratio were calculated. Mid-arm muscle area was calculated from triceps skinfold and mid-arm circumference [30] . Percentage body fat was calculated from the sum of four skinfolds (triceps, biceps, subscapular, suprailiac) and was also measured directly by air displacement plethysmography (Life Measurement Instruments, Concord, Massachusetts, USA) [31, 32] .
Statistical analysis
All statistical analyses were performed using StatView 4.5 software (Abacus Concepts, Inc., Berkeley, California, USA). HIV-1 viral loads were log 10 transformed. Paired t-tests for means or Wilcoxon signed rank tests (if data were not normally distributed) were used to compare variables at the two timepoints. Simple regression analyses were conducted between change in lipid (total cholesterol, LDL cholesterol, and triglyceride) levels and duration of HAART interruption. P values of < 0.05 were considered statistically signi®cant; reported P values are two-tailed. Analyses included data from all 26 patients unless otherwise indicated.
Results
Baseline characteristics
Twenty-six Caucasian men participated in the study (Table 1 ). The mean age of the participants was 45.2 years (range 31 to 63). At the time of study enrollment they had a mean duration of known HIV-1 infection of 7.7 years (range 1.7±14.0). All baseline HIV-1 viral loads were , 50 copies/ml. Baseline median CD4 cell count was 755 3 10 6 cells/l (range 322±1740) and CD4 cell count percentage was 39% (range 23±55). The geometric mean of highest recorded viral loads was 5.00 log 10 copies/ml (range 3.92±6.88), and the mean lowest recorded CD4 cell count was 294 3 10 6 cells/l (range 60±582).
Duration between metabolic measurements was a median 7.0 weeks (range 4.9±10.3); all other measurements were made close to these measurements and prior to reinitiation of HAART. Baseline (and end-ofstudy) metabolic and anthropometric parameters were comparable between the patients who had interrupted HAART for 7.0 weeks and those who had interrupted HAART for less than 7.0 weeks. For the two patients (Patients 24 and 26) who had not yet reached the criteria to restart antiretroviral therapy, end-of-study measurements were made after week 8 as predetermined in the protocol. All 24 patients who had restarted HAART did so because of increasing HIV-1 viral loads to > 5000 copies/ml. Five (19.2%) patients were on a lipid-lowering agent (atorvastatin, pravastatin, or niacin) at baseline; one of these patients discontinued the medication during the study. Eleven (42.3%) patients were taking androgens during the study (testosterone, nandrolone, androstenedione, dehydroepiandrosterone). Baseline metabolic and anthropometric parameters were comparable between the patients who were taking androgens during the study and those who were not. One patient had been taking glimepiride but discontinued it just before the start of the study. During the study, only the one patient, who had been on glimepiride prior to the study, met standard criteria for diabetes mellitus [33] . However, 11 (42.3%) patients had baseline evidence of insulin resistance as measured by HOMA-IR. Nevertheless, there were no signi®cant changes from baseline in glucose levels, insulin levels, glucose AUC, insulin AUC, or HOMA-IR values (Table 2 ).
Metabolic studies
When cortisol excretion was examined, there was a signi®cant increase in 24-h urinary free cortisol (45 AE 34.1 versus 62 AE 32.2 ìg/24 h; P 0.016; n 22) and decrease in 24-h urinary 17-OHCS (15 AE 7.9 versus 5 AE 2.5 mg/24 h; P , 0.0001; n 25) after the period of HAART interruption (Table 2) .
Fat redistribution
Seventeen (65.4%) patients reported at least one fat redistribution symptom at baseline: seven (26.9%) with increased abdominal girth, two (7.7%) with a dorsocervical fat pad, 10 (38.5%) with facial fat loss, and four (15.4%) with extremity fat loss. Overall, nine (34.6%) patients reported symptoms of lipohypertrophy and 13 (50%) reported symptoms of lipoatrophy. Among 17 patients who had an abdominal CT scan performed at baseline, median VAT was 10579 mm 2 (range 3538± 40365) and median TAT was 23 850 (range 10 324± 56 795). Thirteen (76.5%) of the 17 patients had an abnormal VAT:TAT ratio (. 0.4) at baseline. Twelve (46.2%) patients had body mass index . 25 kg/m 2 at baseline; none had body mass index , 18 kg/m 2 . Fourteen (53.8%) patients had waist to hip ratio . 0.95 at baseline. Five (22%) had baseline percentage body fat . 20% as measured by air displacement plethysmography, and 10 (38.5%) had baseline percentage body fat . 20% as calculated from the sum of four skinfolds. No clinically signi®cant changes were observed in any of the anthropometric measurements after HAART interruption (Table 2) . Although there was a statistically signi®cant decrease in the waist to hip ratio after HAART cessation, the difference was within 
Discussion
A relatively brief interruption of HAART in patients with well-controlled HIV infection resulted in a signi®cant decrease in total cholesterol, LDL cholesterol, and triglyceride levels. In addition, there was a signi®-cant increase in 24-h urinary free cortisol and a signi®-cant decrease in 24-h urinary 17-OHCS. However, no changes were observed in insulin resistance pro®les or anthropometric measurements, perhaps because of the relatively brief duration of HAART interruption in our study.
To our knowledge, this is the ®rst study to examine the reversibility of metabolic and fat distribution 
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abnormalities after interruption of HAART. Reversibility of lipoatrophy with discontinuation of stavudine has previously been reported [21] , as has reversal of metabolic abnormalities when PI-based HAART regimens are changed to NNRTI-based regimens [34±36].
It has previously been suggested that the metabolic and fat distribution abnormalities are a result of chronic HIV infection itself [22] . Our results support those of others who have suggested that hyperlipidemia in the setting of HAART is a drug effect that reverses with drug withdrawal [37] . In addition, we previously reported that patients with lipodystrophy had normal diurnal serum cortisol secretion but decreased urinary cortisol excretion and increased 17-OHCS excretion [7] . We have now shown that this pattern is reversible with withdrawal of HAART for a relatively short period of time, suggesting that these alterations in cortisol metabolism are also a direct drug effect. Moreover, because we had found normal diurnal plasma cortisol levels (and normal plasma cortisol in response to ovine corticotropin-releasing hormone) [7] , we believe the alterations in cortisol excretion are unlikely to be involved in the pathogenesis of the metabolic and fat distribution abnormalities seen with HAART.
PI-sparing antiretroviral regimens have been associated with fat redistribution symptoms, without associated changes in lipid or insulin resistance pro®les [21, 38] . These data emphasize the need for future studies to examine the role of speci®c antiretrovirals in fat distribution and metabolic abnormalities.
Generalizations of these ®ndings may be limited by the relatively short duration of HAART interruption as well the small size and limited demographic pro®le of the study population. However, the duration of HAART interruption was limited by the prospectively determined virologic and immunologic safety criteria. There has been some evidence that there are gender differences in the metabolic and fat distribution abnormalities, with women acquiring symptoms of lipohypertrophy, and men tending to have hyperlipidemia and symptoms of lipoatrophy [39] . In addition, there was no control for concurrent medications. Although baseline metabolic and anthropometric parameters were comparable between different subgroups of patients, the number of patients in these subsets was small and limited the validity of these comparisons. Similarly, ®ve patients were taking a lipid-lowering agent during the study. However, the statistically signi®cant improvements in total cholesterol, LDL cholesterol, and triglyceride levels after HAART cessation remained when the data were analyzed excluding these ®ve patients.
It is still unclear whether the metabolic and fat distribution abnormalities that have been noted in HIVinfected patients are a single syndrome or are the result of multiple associated but distinct syndromes. Investigators are now reassessing the framework within which to guide future investigation [10, 40] , particularly with regard to the long-term effects of these abnormalities on morbidity and mortality. Studies examining the potential virologic and immunologic bene®ts of multiple sequential HAART interruptions are currently underway. It will be important to determine whether any clinically signi®cant improvements in metabolic and body composition parameters will occur with this intermittent approach to HAART. Our data suggest that these trials may show at least transient improvements in some metabolic parameters, although the long-term bene®ts of these changes are yet to be determined.
